3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
86
Breast Neoplasms
15
Neoplasms
6
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Salivary Gland Neoplasms
2
Prostate Adenocarcinoma
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Hodgkin Disease
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urogenital Neoplasms
1
Skin Neoplasms
1
Skin Diseases
1
Salivary Gland Neoplasm Duct
1
Recurrence
1
Rare Diseases
1
Prostatic Diseases
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
PSA Level Greater Than Two
1
Obesity, Morbid
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Interventions
Fulvestrant
3
Alpelisib
3
parsaclisib
2
Paclitaxel
2
Irinotecan
2
Cetuximab
2
Carboplatin
2
tanezumab
1
talazoparib
1
sotorasib
1
serabelisib
1
sapanisertib
1
ruxolitinib
1
olaparib
1
niraparib
1
liposomal doxorubicin
1
inavolisib
1
dapagliflozin
1
ceralasertib
1
binimetinib
1
berzosertib
1
avelumab
1
Vemurafenib
1
Topotecan
1
Taxes
1
SF 1126
1
Oxaliplatin
1
Lomustine
1
Leuprolide
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hereditary Sensory and Autonomic Neuropathies
×
Leuprolide
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts